AI assistant
Sending…
Galapagos NV — Annual Report 2020
Feb 18, 2021
3954_rns_2021-02-18_9a79f2ee-a6d6-4f4d-93f6-13ba477d034e.pdf
Annual Report
Open in viewerOpens in your device viewer

Consolidated financial statements
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME/LOSS (-)
Consolidated income statement
| Year ended 31 December | ||
|---|---|---|
| (thousands of €, except per share data) | 2020 | 2019 (*) |
| Revenues | 478,053 | 834,901 |
| Other income | 52,207 | 50,896 |
| Total revenues and other income | 530,260 | 885,797 |
| Research and development expenditure | (523,667) | (420,090) |
| Sales and marketing expenses | (66,468) | (24,577) |
| General and administrative expenses | (118,757) | (72,382) |
| Total operating expenses | (708,892) | (517,049) |
| Operating profit/loss (-) | (178,632) | 368,748 |
| Fair value re-measurement of share subscription agreement and warrants | 3,034 | (181,644) |
| Other financial income | 18,667 | 21,389 |
| Other financial expenses | (152,844) | (59,968) |
| Profit/loss (-) before tax | (309,775) | 148,525 |
| Income taxes | (1,226) | 165 |
| Net profit/loss (-) from continuing operations | (311,001) | 148,689 |
| Net profit from discontinued operations, net of tax | 5,565 | 1,156 |
| Net profit/loss (-) | (305,436) | 149,845 |
| Net profit/loss (-) attributable to: | ||
| Owners of the parent | (305,436) | 149,845 |
| Basic income/loss (-) per share | (4.69) | 2.60 |
| Diluted income/loss (-) per share | (4.69) | 2.49 |
| Basic income/loss (-) per share from continuing operations | (4.78) | 2.58 |
| Diluted income/loss (-) per share from continuing operations | (4.78) | 2.47 |
(*) The 2019 comparatives have been restated to consider the impact of classifying the Fidelta business as discontinued operations in 2020.
Consolidated statement of comprehensive income/loss (-)
| Year ended 31 December | ||
|---|---|---|
| (thousands of €) | 2020 | 2019 (*) |
| Net profit/loss (-) | (305,436) | 149,845 |
| Items that will not be reclassified subsequently to profit or loss: | ||
| Re-measurement of defined benefit obligation | (6,065) | (4,107) |
| Items that may be reclassified subsequently to profit or loss: | ||
| Translation differences, arisen from translating foreign activities | (1,024) | 415 |
| Realization of translation differences upon liquidation of foreign operations | (1,023) | – |
| Other comprehensive income/loss (-), net of income tax | (8,112) | (3,692) |
| Total comprehensive income/loss (-) attributable to: | ||
| Owners of the parent | (313,548) | 146,154 |
| Total comprehensive income/loss (-) attributable to owners of the parent arises from: | ||
| Continuing operations | (318,841) | 145,050 |
| Discontinued operations | 5,293 | 1,104 |
| Total comprehensive income/loss (-), net of income tax | (313,548) | 146,154 |
(*) The 2019 comparatives have been restated to consider the impact of classifying the Fidelta business as discontinued operations in 2020.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
Assets
| 31 December | 31 December | |
|---|---|---|
| (thousands of €) | 2020 | 2019 |
| Intangible assets | 67,565 | 24,927 |
| Property, plant and equipment | 103,378 | 66,052 |
| Deferred tax assets | 4,475 | 4,205 |
| Non-current trade receivables | 50,000 | – |
| Non-current R&D incentives receivables | 111,624 | 93,407 |
| Other non-current assets | 11,343 | 14,091 |
| Non-current assets | 348,384 | 202,682 |
| Trade and other receivables | 148,418 | 54,009 |
| Current R&D incentives receivables | 24,104 | 21,949 |
| Current financial investments | 3,026,278 | 3,919,216 |
| Cash and cash equivalents | 2,135,187 | 1,861,616 |
| Other current assets | 11,953 | 9,138 |
| Current assets from continuing operations | 5,345,941 | 5,865,927 |
| Assets classified as held for sale | 23,406 | – |
| Total current assets | 5,369,347 | 5,865,927 |
| Total assets | 5,717,731 | 6,068,609 |

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
Equity and liabilities
| 31 December | 31 December | |
|---|---|---|
| (thousands of €) | 2020 | 2019 |
| Share capital | 291,312 | 287,282 |
| Share premium account | 2,727,840 | 2,703,583 |
| Other reserves | (10,907) | (4,842) |
| Translation differences | (3,189) | (1,142) |
| Accumulated losses | (334,701) | (109,223) |
| Total equity | 2,670,355 | 2,875,658 |
| Retirement benefit liabilities | 14,996 | 8,263 |
| Non-current lease liabilities | 23,035 | 19,558 |
| Other non-current liabilities | 8,096 | 6,989 |
| Non-current deferred income | 2,365,974 | 2,586,348 |
| Non-current liabilities | 2,412,101 | 2,621,158 |
| Current lease liabilities | 6,401 | 5,826 |
| Trade and other liabilities | 172,386 | 143,434 |
| Current tax payable | 1,248 | 2,037 |
| Current financial instruments | 3,164 | 6,198 |
| Current deferred income | 443,159 | 414,298 |
| Current liabilities from continuing operations | 626,357 | 571,793 |
| Liabilities directly associated with assets classified as held for sale | 8,917 | – |
| Total current liabilities | 635,274 | 571,793 |
| Total liabilities | 3,047,375 | 3,192,951 |
| Total equity and liabilities | 5,717,731 | 6,068,609 |

CONSOLIDATED CASH FLOW STATEMENT
| (thousands of €) | 2020 | 2019 |
|---|---|---|
| Net profit/loss (-) of the year | (305,436) | 149,845 |
| Adjustment for non-cash transactions | 230,723 | 248,027 |
| Adjustment for items to disclose separately under operating cash flow | 4,067 | (7,731) |
| Adjustment for items to disclose under investing and financing cash flows | (2,472) | (5,061) |
| Change in working capital other than deferred income | (146,092) | 12,698 |
| Increase/decrease (-) in deferred income | (207,787) | 2,804,202 |
| Cash generated/used (-) in operations | (426,998) | 3,201,980 |
| Interest paid | (9,033) | (1,158) |
| Interest received | 10,054 | 7,852 |
| Corporate taxes paid | (1,358) | (57) |
| Net cash flows generated/used (-) in operating activities | (427,336) | 3,208,617 |
| Purchase of property, plant and equipment | (42,522) | (22,385) |
| Purchase of and expenditure in intangible fixed assets | (48,793) | (23,300) |
| Proceeds from disposal of property, plant and equipment | 49 | – |
| Purchase of current financial investments | (4,574,206) | (4,787,284) |
| Interest received related to current financial investments | 3,500 | 5,059 |
| Sale of current financial investments | 5,415,316 | 1,063,344 |
| Acquisition of financial assets | (2,681) | (177) |
| Proceeds from sale of financial assets held at fair value through profit or loss | 6,626 | 82 |
| Net cash flows generated/used (-) in investing activities | 757,288 | (3,764,660) |
| Payment of lease liabilities | (6,247) | (5,091) |
| Proceeds from capital and share premium increases, gross amount | – | 960,087 |
| Issue costs paid related to capital and share premium increases | – | (4,447) |
| Proceeds from capital and share premium increases from exercise of subscription rights | 28,287 | 17,167 |
| Proceeds from capital and share premium increases from exercise of warrant A by Gilead | – | 368,035 |
| Net cash flows generated in financing activities | 22,040 | 1,335,751 |
| Increase in cash and cash equivalents | 351,994 | 779,708 |

| (thousands of €) | 2020 | 2019 |
|---|---|---|
| Cash and cash equivalents at beginning of year | 1,861,616 | 1,290,796 |
| Transfer to current financial investments | – | (198,922) |
| Increase in cash and cash equivalents | 351,994 | 779,708 |
| Effect of exchange rate differences on cash and cash equivalents | (70,539) | (9,966) |
| Cash and cash equivalents at end of the year | 2,143,071 | 1,861,616 |
Note to the consolidated cash flow statement
| 31 December | 31 December | |
|---|---|---|
| (thousands of €) | 2020 | 2019 |
| Current financial investments | 3,026,278 | 3,919,216 |
| Cash and cash equivalents | 2,135,187 | 1,861,616 |
| Cash and cash equivalents classified as assets held for sale | 7,884 | – |
| Current financial investments and cash and cash equivalents | 5,169,349 | 5,780,832 |
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
| (thousands of €) | Share capital | Share premium account |
Translation differences |
Other reserves |
Accumul. losses |
Total |
|---|---|---|---|---|---|---|
| On 1 January 2019 | 236,540 | 1,277,780 | (1,557) | (735) | (297,779) | 1,214,249 |
| Change in accounting policy (modified retrospective applica tion IFRS 16) |
416 | 416 | ||||
| Restated total equity at 1 January 2019 |
236,540 | 1,277,780 | (1,557) | (735) | (297,363) | 1,214,665 |
| Net profit | 149,845 | 149,845 | ||||
| Other comprehensive income/ loss (-) |
415 | (4,107) | (3,692) | |||
| Total comprehensive income/ loss (-) |
415 | (4,107) | 149,845 | 146,154 | ||
| Share-based compensation | 38,297 | 38,297 | ||||
| Derecognition of financial liability from share subscription agreement and warrant A |
135,702 | 135,702 | ||||
| Issue of new shares | 36,945 | 923,142 | 960,087 | |||
| Share issue costs | (4,447) | (4,447) | ||||
| Exercise of warrant A by Gilead | 14,162 | 353,873 | 368,035 | |||
| Exercise of subscription rights | 4,082 | 13,085 | 17,167 | |||
| On 31 December 2019 | 287,282 | 2,703,583 | (1,142) | (4,842) | (109,223) | 2,875,658 |
| On 1 January 2020 | 287,282 | 2,703,583 | (1,142) | (4,842) | (109,223) | 2,875,658 |
| Net loss | (305,436) | (305,436) | ||||
| Other comprehensive loss | (2,047) | (6,065) | (8,112) | |||
| Total comprehensive loss | (2,047) | (6,065) | (305,436) | (313,548) | ||
| Share-based compensation | 79,959 | 79,959 | ||||
| Exercise of subscription rights | 4,031 | 24,257 | 28,288 | |||
| On 31 December 2020 | 291,312 | 2,727,840 | (3,189) | (10,907) | (334,701) | 2,670,355 |
More from Galapagos NV
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Apr 29
Declaration of Voting Results & Voting Rights Announcements
2026
Apr 29
Declaration of Voting Results & Voting Rights Announcements
2026
Apr 29
M&A Activity
2026
Mar 31
M&A Activity
2026
Mar 31
Regulatory Filings
2026
Mar 30
Board/Management Information
2026
Mar 27